ACR/NPF Treatment of Psoriatic Arthritis Guideline Summary

Table 1. Recommendations for the Initial Treatment of Patients With Active PsA Who Are OSM- and Other Treatment-Naïve

In OSM- and other treatment–naïve patients with active PsA:

Treat with a TNFi biologic over an OSM (MTX, SSZ, LEF, CSA, or APR)

May consider an OSM if the patient does not have severe PsA, does not have severe psoriasis, prefers oral therapy, has concern over starting a biologic as the first therapy, or has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease. ( Conditional , Low )

607

Treatment of Psoriatic Arthritis

Table 1. Recommendations for the Initial Treatment of Patients With Active PsA Who Are OSM- and Other Treatment-Naïve

In OSM- and other treatment–naïve patients with active PsA:

Treat with a TNFi biologic over an OSM (MTX, SSZ, LEF, CSA, or APR)

Table 2. Recommendations for Treatment of Patients With Active PsA Despite Treatment With an OSM

In adult patients with active PsA despite treatment with an OSM

Overview

Title

Authoring Organizations